Natera (NASDAQ: NTRA ) is a genetic testing company, with focuses on oncology, women's health, and organ health. Their signature product, Signatera, can help predict the efficacy of many forms of cancer treatment. Natera has alsoLike millions of other investors, I got Robinhood and started trading during the pandemic. Unlike most of those investors, I carefully studied hundreds of earnings reports for clues to future performance, and I was able to identify many future winners, such as OPRX, OTRK, FUBO, and ...

广东利扬芯片测试股份有限公司 （广东省东莞市万江街道莫屋新丰东二路 2 号） 会议资料 股票简称：利扬芯片 股票代码：688135 二零二五年五月三十日 广东利扬芯片测试股份有限公司 2024 年年度股东大会会议资料 目 录 议案九：《关于 2025 年度公司及子公司申请综合授信额度并提供担保的议案》15 议案十：《关于提请股东大会授权董事会办理以简易程序向特定对象发行股票的 广东利扬芯片测试股份有限公司 2024 年年度股东大会会议资料 广东利扬芯片测试股份有限公司 为维护全体股东的合法权益，确保股东大会会议秩序和议事效率，保证股东 大会的顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）中国证监会《上市公司 股东大会规则》以及《广东利扬芯片测试股份有限公司章程》（以下简称"《公 司章程》"）和《广东利扬芯片测试股份有限公司股东大会议事规则》等有关规 定，特制定本次广东利扬芯片测试股份有限公司（以下简称"公司"）股东大会 会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作 ...

Company surpasses 450 accounts across 24 countries as global demand for fingerprint drug testing surgesNEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced recent growth highlights across its global operations, driven by new account acquisitions, expansion into new testing areas and sectors, and continued penetration into safety-critical i ...

如果您希望可以时常见面，欢迎标星收藏哦~ 前言 是德科技大中华区市场总经理郑纪峰 AI风口背后， 是一个"带病运行"的数据中心 "如今，AI训练集群已经不是千卡、万卡，而是十万卡。一个投资200亿的数据中心集群， GPU如果有一半时间在等数据，这不仅仅是算力的问题，这是资产浪费、运营灾难。"是德 科技高速数字市场部经理李坚指出。在AI算力革命的表面繁荣下，隐藏着连接、运维、稳定 性的隐秘挑战。AI基础设施背后还有很多需要提升的空间，而 这些提升空间，就藏在今天 尚不健全的测试、验证、优化环节里。 十年跃迁，是德科技站上AI风口 从2014年脱胎于安捷伦，成为专注电子测试的独立公司，到如今跃迁为一家以软件为核心、横跨 通信、半导体、汽车电子、AI等多个领域的测试测量公司。2025年，是德科技走过了独立运营的 第十个年头。一个十年的周期，对一家以工程师思维著称的电子测试巨头而言，或许不算长，却足 以让它完成一次从"硬件图腾"到"软件中枢"的自我重塑。是德科技大中华区市场总经理郑纪峰先生 回顾了是德科技的"十年独立进化史"。 是德科技过去十年的精彩时刻 （图源：是德科技，下同） 这十年，是德科技完成了20余宗并购， ...

NV5 Global (NVEE) M&A Announcement May 14, 2025 08:00 PM ET Speaker0 and welcome to the Akron Corporation First Quarter Earnings and Merger Announcement Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Scott, Investor Relations with ICR. Thank you. You may begin. Speaker1 Operator, good morning, everyone, and thank you for joini ...

Bionano Genomics (BNGO) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants David Holmes - Managing DirectorErik Holmlin - President and Chief Executive OfficerVidyun Bais - Equity Research - Vice PresidentJoanne Lee - Biotech Equity Research Associate Conference Call Participants Sung Ji Nam - Managing Director, Senior Equity Research Analyst Operator Good day, and welcome to the Bionana First Quarter twenty twenty five Earnings Conference Call. Today's conference is being recorded. At this ...

Lucid Diagnostics (LUCD) Q1 2025 Earnings Call May 14, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the Lucid Diagnostics First Quarter twenty twenty five Business Update Conference Call. Please note this event is being recorded. I would now like to turn the conference call over to Mr. Matt Reilly, Lucid Diagnostics Senior Director of Investor Relations. Please go ahead. Speaker1 Thank you, operator. Good morning, everyone. Thank you for participating in today's business update call. Joining me to ...

Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settingsVANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into an exclusive distribution agreement (“Agreement”) with Breathalyser Sales & Service Pty Ltd., (“Breathalyser SSP”) for ...

Core Insights - Teradyne's international operations are crucial for assessing its financial strength and growth potential, especially given its global presence in wireless products, data storage, and semiconductor testing equipment [1][2] Revenue Performance - Teradyne's total revenue for the quarter ending March 2025 was $685.68 million, reflecting a year-over-year increase of 14.3% [4] - Asia Pacific contributed significantly, accounting for 77.65% of total revenue, which is $532.41 million, and exceeded Wall Street's expectations by 12.77% [5] - Revenue from Asia Pacific in the previous quarter was $557.32 million (74.03%) and $423.67 million (70.63%) in the same quarter last year [5] - Europe, Middle East, and Africa generated $43.36 million, representing 6.32% of total revenue, which was a decline of 45.09% compared to the expected $78.96 million [6] - In the previous quarter, this region accounted for $65.57 million (8.71%) and $67.49 million (11.25%) in the year-ago quarter [6] Future Projections - Analysts project Teradyne's total revenue for the current fiscal quarter to be $646.18 million, indicating an 11.5% decline from the prior year [7] - Expected revenue shares from Asia Pacific and Europe, Middle East, and Africa are 78.6% ($507.83 million) and 8.8% ($57.12 million), respectively [7] - For the full year, total revenue is anticipated to reach $2.92 billion, a 3.5% increase from the previous year, with Asia Pacific and Europe, Middle East, and Africa expected to contribute $2.23 billion (76.5%) and $288.79 million (9.9%) [8] Conclusion - Teradyne's reliance on international markets presents both opportunities and risks, making it essential to monitor international revenue trends for forecasting the company's future prospects [9][10]

20% sequential quarterly revenue growth and 91% year-over-year quarterly gross profit growth Continued momentum from recurring higher-margin cartridge sales now reaching 58% of total sales for the nine months ended March 31, 2025 35 new accounts and international growth during Q3 bring total active accounts to over 450 NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive t ...